NASDAQ:AMED - Amedisys Stock Price, Forecast & News

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys Inc (NASDAQ:AMED) issued its quarterly earnings results on Tuesday, October, 29th. The health services provider reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.90 by $0.25. The health services provider earned $494.63 million during the quarter, compared to analyst estimates of $494.14 million. Amedisys had a return on equity of 26.53% and a net margin of 6.70%. The firm's quarterly revenue was up 18.5% on a year-over-year basis. During the same period last year, the company posted $0.95 EPS. View Amedisys' Earnings History.

Amedisys is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Amedisys.

Amedisys will be holding an earnings conference call on Tuesday, February 18th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

12 Wall Street analysts have issued 1-year price targets for Amedisys' shares. Their forecasts range from $124.00 to $206.00. On average, they anticipate Amedisys' share price to reach $161.38 in the next year. This suggests that the stock has a possible downside of 18.4%. View Analyst Price Targets for Amedisys.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amedisys.

Media coverage about AMED stock has been trending somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amedisys earned a news sentiment score of 1.8 on InfoTrie's scale. They also assigned news articles about the health services provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Amedisys.

Amedisys saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 1,180,000 shares, a decrease of 7.8% from the January 15th total of 1,280,000 shares. Based on an average daily volume of 235,400 shares, the short-interest ratio is presently 5.0 days. Currently, 3.7% of the shares of the stock are sold short. View Amedisys' Current Options Chain.

Some companies that are related to Amedisys include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), BioScrip (BIOS), Davita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), R1 RCM (RCM), CorVel (CRVL), Tivity Health (TVTY), The Providence Service (PRSC), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), Cisco Systems (CSCO), NVIDIA (NVDA), Verizon Communications (VZ), Netflix (NFLX), QUALCOMM (QCOM), Micron Technology (MU), Adobe (ADBE), Baidu (BIDU) and CVS Health (CVS).

Amedisys' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (3.32%), State Street Corp (3.12%), Riverbridge Partners LLC (2.06%), Bank of America Corp DE (1.35%), Bank of New York Mellon Corp (1.19%) and Eagle Asset Management Inc. (0.89%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North, Scott G Ginn and Sharon Brunecz. View Institutional Ownership Trends for Amedisys.

AMED stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, AQR Capital Management LLC, FMR LLC, Marshall Wace LLP, Rothschild & Co. Asset Management US Inc., Marshall Wace North America L.P., Eaton Vance Management and 361 Capital LLC. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn and Sharon Brunecz. View Insider Buying and Selling for Amedisys.

AMED stock was purchased by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Castleark Management LLC, William Blair Investment Management LLC, British Airways Pensions Investment Management Ltd, Columbus Circle Investors, Renaissance Technologies LLC, Great Lakes Advisors LLC and Knights of Columbus Asset Advisors LLC. View Insider Buying and Selling for Amedisys.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AMED stock can currently be purchased for approximately $197.88.

Amedisys has a market capitalization of $6.38 billion and generates $1.66 billion in revenue each year. The health services provider earns $119.35 million in net income (profit) each year or $3.63 on an earnings per share basis. Amedisys employs 21,000 workers across the globe.View Additional Information About Amedisys.

The official website for Amedisys is http://www.amedisys.com/.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]